Novo Nordisk: diabetes pill shows positive results in trials
(CercleFinance.com) - Novo Nordisk's oral semaglutide showed statistically significantly greater reductions in blood sugar levels and weight compared to existing type-2 diabetes drugs in a pair of large studies, according to data presented on Thursday.
In a 52-week phase 3 trial in 711 people with type-2 diabetes, oral semaglutide showed a non-inferior reduction in HbA1c and statistically significant and superior weight loss at 26 weeks compared to Novo's Victoza.
Another 52-week trial in 504 people with type-2 diabetes achieved its primary endpoint by demonstrating that oral semaglutide was statistically significant and superior to Merck's sitagliptin.
"Both results confirmed the strong efficacy of oral semaglutide and its potential to become a leader in diabetes oral treatment," analysts at Bryan Garnier said.
"We estimate oral semaglutide could replace a lot of existing oral treatments," they added.
The Copenhagen-listed shares of Novo Nordisk are currently up 4.5% at 301.5 Danish kronor.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
In a 52-week phase 3 trial in 711 people with type-2 diabetes, oral semaglutide showed a non-inferior reduction in HbA1c and statistically significant and superior weight loss at 26 weeks compared to Novo's Victoza.
Another 52-week trial in 504 people with type-2 diabetes achieved its primary endpoint by demonstrating that oral semaglutide was statistically significant and superior to Merck's sitagliptin.
"Both results confirmed the strong efficacy of oral semaglutide and its potential to become a leader in diabetes oral treatment," analysts at Bryan Garnier said.
"We estimate oral semaglutide could replace a lot of existing oral treatments," they added.
The Copenhagen-listed shares of Novo Nordisk are currently up 4.5% at 301.5 Danish kronor.
Copyright (c) 2018 CercleFinance.com. All rights reserved.